The in vivo performance of the 177Lu-PSMA-617 was characterized by high and retained tumor uptake combined with a rapid clearance from the kidneys within 24 h p.i., which led to improved tumor to background ratios over time (1058 (tumor to blood) and 529 (tumor to muscle), 24 h p.i.). This evidence concerns the gene FOLH1 and neoplasm.